Fundraising FoxProteostasis Therapeutics
acquired by Yumanity Therapeutics5 known investors
Find your way into Proteostasis Therapeutics
Sign up to see every warm intro you have to Proteostasis Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Proteostasis Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Yumanity Therapeutics December 2020 · $150M (approximately $150 million (reverse merger, per secondary source)) · source ↗
Developing disease-modifying therapeutics for diseases of protein processing, with a lead program in cystic fibrosis.
Investors · 5
Avoro Capital Advisorslisted by Avoro Capital AdvisorsNew York
How we know: Avoro Capital Advisors's portfolio page · Not right? Tell us
F-Prime Capitallisted by F-Prime CapitalCambridge · $3M – $10M
How we know: F-Prime Capital's portfolio page · Not right? Tell us
Sanofi Ventureslisted by Sanofi VenturesCambridge · $5M
How we know: Sanofi Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
Frequently asked questions
- What does Proteostasis Therapeutics do?
- Developing disease-modifying therapeutics for diseases of protein processing, with a lead program in cystic fibrosis.
- Who are Proteostasis Therapeutics's investors?
- Proteostasis Therapeutics's investors include Avoro Capital Advisors, F-Prime Capital, New Enterprise Associates (NEA), Sanofi Ventures, Sofinnova Ventures.
- Who acquired Proteostasis Therapeutics?
- Proteostasis Therapeutics was acquired by Yumanity Therapeutics.